
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences is demonstrating durable fundamental momentum through an 11% Q3 revenue beat to $103M, 24% year-over-year revenue growth, and adjusted EBITDA of about $13M, showing that the business is scaling profitably while maintaining a 77% gross margin. The outlook is supported by multiple growth engines, led by TissueCypher’s 47% volume growth, DecisionDx-Melanoma’s fifth consecutive quarter above 10,000 tests, and early adoption of AdvanceAD-Tx, while management also raised 2026 revenue guidance to $385M-$395M. Reimbursement progress and pricing power add further upside, with potential SCC Medicare coverage in 2028, a strong crosswalk case for atopic dermatitis, and $278M of cash providing flexibility to invest prudently while still expecting positive adjusted EBITDA in Q4’26, FY2026, and FY2027.
Bears say
Castle Biosciences is facing a material reimbursement overhang because meaningful revenue from its SCC test is excluded after April 24, 2025, when Medicare payments stopped through Novitas, creating direct pressure on top-line visibility. The uncertainty around Medicare coverage for SCC is especially concerning because it is outside both the company’s guidance and the estimates, implying that near-term expectations may still prove too optimistic. More broadly, the company remains exposed to fluctuating government and commercial reimbursement rates, slow physician and payer adoption of new tests, competitive share loss, and the possibility that operating losses could require additional capital that may not be available.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Castle Biosciences Inc (CSTL) Forecast
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares